10-Q · May 15, 2026
Rein Therapeutics reported a net loss of $5.8 million for Q4 2026, an increase from $5.5 million in the same quarter last year. The company continues to operate at a loss without revenue generation, indicating ongoing…
Earnings analysis · 10-Q
RNTX earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q text provides no income-statement, balance-sheet, cash-flow, segment, or quantitative guidance data, so financial performance cannot be assessed from the supplied filing content. The key disclosure is…
Read full summary
The extracted 10-Q text provides no income-statement, balance-sheet, cash-flow, segment, or quantitative guidance data, so financial performance cannot be assessed from the supplied filing content. The key disclosure is that disclosure controls were not effective as of June 30, 2026, with 2 material weaknesses continuing from December 31, 2025. Management is pursuing remediation, including third-party support and fiscal-year 2026 control testing, but gives no assurance that remediation will succeed or that additional weaknesses will not be identified.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Material weaknesses disclosed
Management identified 2 continuing material weaknesses in internal control over financial reporting: insufficient technical accounting and supervisory personnel, and inadequate procedures for timely preparation and review of financial statements.
-
Third-party remediation support
The company engaged 1 third party to assess control design and implementation, develop remediation plans, and support control-gap remediation.
-
Remediation work planned for 2026
Management expects to continue control enhancements and test operating effectiveness, including IT general controls, during fiscal year 2026.
What to watch
-
Ineffective disclosure controls
Disclosure controls were not effective at the reasonable-assurance level as of June 30, 2026 because of the identified material weaknesses, creating a risk that financial statement errors may not be prevented or detected timely.
-
Weaknesses remain unresolved
The 2 material weaknesses continued to exist at both June 30, 2026 and December 31, 2025, indicating that remediation has not yet been completed.
-
Remediation execution uncertainty
Management states that no assurance can be given that remediation will occur or that additional material weaknesses will not be identified; planned testing and supplemental resources are expected during fiscal year 2026.
Management's outlook
No quantitative revenue or EPS outlook is provided in the extracted 10-Q text. The company states that additional internal-control remediation activities are expected to be completed in fiscal year 2026.
Earlier filings 4
10-K · April 27, 2026
Rein Therapeutics is a clinical-stage biopharma focused on LTI‑03 for idiopathic pulmonary fibrosis with an active Phase 2 program (RENEW). Management highlights positive early biomarker signals and regulatory progress,…
10-K · March 26, 2026
Rein Therapeutics is a clinical-stage biopharma prioritizing LTI-03 (Cav1‑derived peptide) for idiopathic pulmonary fibrosis; positive Phase 1a/1b biomarker signals and a Phase 2 (RENEW) program are underway (RENEW…
10-Q · November 14, 2025
Rein Therapeutics reported no revenue and a narrower GAAP loss in Q3 2025: net loss of $(5,581) and loss per share of $(0.21) versus $(5,847) and $(0.27) in Q3 2024. Operating expense reductions (notably R&D) and a…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.